Eli Lilly

LLY

Market cap $968B

Eli Lilly chairman and CEO David Ricks joins 'Squawk on the Street' to discuss the path to becoming a trillion dollar company, launch of its obesity pill, new innovation at the company, drug pipeline outlook, and more.

Eli Lilly and Novo Nordisk make the world's most popular weight loss drugs. These injectable products have generated double-digit growth, with revenue reaching blockbuster levels.

Novo Nordisk launched an oral version of its best-selling weight management medicine. It may not help catch up to Eli Lilly, whose oral anti-obesity drug is also expected to hit the market soon.

Eli Lilly (LLY) concluded the recent trading session at $1, signifying a +1.64% move from its prior day's close.

Pill versions of the successful GLP1 drugs from Novo Nordisk and Eli Lilly will likely be on the market in 2026's first half.

Nvidia plans to invest $1 billion over five years in a new laboratory with Eli Lilly & Co., in an effort to speed up the use of AI in the pharmaceutical industry. Denny Fish, portfolio manager on the Global Technology and Innovation Team at Janus Henderson Investors, joins Caroline Hyde and Ed Ludlow on “Bloomberg Tech.

NVIDIA plans to invest $1 billion over five years in a new laboratory with Eli Lilly and Company, aiming to speed up the use of artificial intelligence in the pharmaceutical industry. Heres what Eli Lilly CFO Lucas Montarce had to say about the partnership.

Nvidia Corp (NASDAQ:NVDA, XETRA:NVD) and Eli Lilly and Co (NYSE:LLY) have announced the creation of a new AI-focused co-innovation lab aimed at accelerating drug discovery and development. The lab will combine Lilly's expertise in medicine discovery, development, and manufacturing with Nvidia's AI and computing capabilities, the companies announced on Monday.

One of the major promises of artificial intelligence (AI) is its role in speeding up drug discovery.

Eli Lilly Chief Financial Officer Lucas Montarce says the company's weight-loss pill is on track to be approved in the US as early as the second quarter of this year. He speaks to Katie Greifeld at the JPMorgan Healthcare Conference in San Francisco.